Navigation Links
Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
Date:9/23/2010

NEW YORK, Sept. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Profiling and Pathways: Technologies and Global Markets

http://www.reportlinker.com/p0298002/Cancer-Profiling-and-Pathways-Technologies-and-Global-Markets.html

BCC estimates the global market for Cancer Profiling Technologies at about $15 billion in 2009. BCC expects the market to reach $17.7 billion in 2010 and $47 billion by 2015, at a compound annual growth rate (CAGR) of 21.6% over the next 5 years.

Proteomics were worth $7.9 billion in 2009. This segment is expected to increase to $9.4 billion in 2010 and reach $19.5 billion by 2015, at a compound annual growth rate (CAGR) of 15.6%.

Genomics were the second-largest application segment, with nearly $6 billion in 2009. While remaining the second-largest market segment, its share of the global market is expected to increase to a $10.5 billion by 2015.

Epigenetics/methylation and microRNA are the other two products where former being the third largest with expected percentage of $17 billion by 2015 and latter being the last with $98.1 million by 2015. 

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report, BIO073A Cancer Profiling and Pathways: Technologies and Global Markets, provides a detailed overview and thorough analysis and insight of the present and future cancer profiling and pathways. This report analyzes in detail the cancer profiling and tools markets. This report includes products in this market, and detailed analyses of markets and competitive environments, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market. The report includes information about significant products, key players, issues and trends, current market status of cancer profiling methods, strengths, weaknesses, opportunities and challenges, major issues involved in the research and development (R&D) of more effective cancer profiling techniques, and new cancer therapeutics in development and in clinical trials.

REASONS FOR DOING THE STUDY

Gene expression profiling methods enable the detection and measurement of multiple expressed gene transcripts in a single RNA sample. Continually evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, are integral to deciphering the molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers. Life Technologies, Applied Biosystems division, and Affymetrix, respectively, are maintaining their leads in the quantitative real-time PCR and microarray market segments. Understanding the multivariate nature of cancer and drug response also depends on molecular profiling at epigenetic, genetic, and protein levels. A major challenge is to develop an understanding of this multivariate dysregulation, with respect both to how it arises from diverse genetic mutations and to how it may be ameliorated by prospective treatments. High-throughput experimental platform technologies ranging from genomic sequencing to transcriptomic, proteomic, and metabolomic profiling are now commonly used for molecular-level characterization of tumor cells and surrounding tissues. The global cancer profiling market is projected to be valued at $40.3 billion by 2015, growing at a compound annual growth rate (CAGR) of 20.8% from 2009 to 2015, driven by the high demand for novel and specific biomarkers in the field of drug discovery. The increasing use of biomarkers in clinical services is boosting the overall biomarker service market. The high growth of the biomarker market is boosted by the demand from the baby boomer generation in the U.S., and from Asia's emerging IT industry.

SCOPE OF REPORT

Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size, and competitive landscape needs a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments. This report's exhaustive market segmentation captures relevant data regarding biomarker tools, services, and application markets, and thereby provides a complete picture of the cancer-profiling market. The proposed report will give an update on Cancer Profiling and Pathways: Technologies and Global Markets. It will review global markets for cancer profiling and biomarker studies and will forecast trends for use of technologies through 2015. Important cancer profiling techniques, market share by type of products on the market and market share by company, information for types of cancers and biomarkers will be provided. The report also includes current issues and trends affecting the industry, costs, and factors influencing demand.. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables and also provides company profiles.

The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics, and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.

INTENDED AUDIENCE

This report is an exhaustive study on the cancer profiling and pathways, giving crucial statistics and analysis on the market structure, market size, key technologies and segments, important trends in technology development, next-generation technologies, major opportunities, and market shares of key players and innovative drugs. This report may prove crucial for the firms or investors seeking investments in the concerned sector. As market needs change with progress, the value of the information provided from microarrays, sequencing, and qRT-PCR has become more interesting for markets outside of basic life-science research. In oncology-expression pattern profiling, comparing expression in normal and cancer tissues shows an unexpected greater reliability in classifying cancer types than the signatures of protein-coding genes. Researchers have also successfully classified poorly differentiated tumors using expression profiles. Along with their diagnostic potential, cancer-profiling techniques have also reportedly proven to be of prognostic value to predict survival among cancer patients and poor responsiveness to adjuvant chemotherapy and other drugs.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to paid databases. The base year of the report is 2009, with forecast data provided through 2015. Historical, base year, and forecast data are provided for each market segment of this report. Growth rates are determined through a compilation of data, including past trends, future trends, products in R&D, and current product growth, etc.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 2

INTENDED AUDIENCE 2

METHODOLOGY 3

RELATED BCC STUDIES 3

ANALYST CREDENTIALS 3

BCC ONLINE SERVICES 3

BCC ONLINE SERVICES 4

DISCLAIMER 4

Chapter-2: SUMMARY

CANCER PROFILING AND PATHWAYS 5

CANCER PROFILING AND PATHWAYS (CONTINUED) 6

SUMMARY TABLE MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2015 ($ MILLIONS) 7

SUMMARY FIGURE MARKET FOR CANCER PROFILING TECHNOLOGIES, 2009–2015 ($ MILLIONS) 7

Chapter-3: OVERVIEW

INTRODUCTION 8

INTRODUCTION (CONTINUED) 9

INTRODUCTION (CONTINUED) 10

LINKING CANCER DISEASE THROUGH PATHWAY PROFILING 11

HISTORICAL FACTS 11

Historical Facts (Continued) 12

Historical Facts (Continued) 13

Historical Facts (Continued) 14

Historical Facts (Continued) 15

CLINICAL UTILITY OF MOLECULAR PROFILING 16

Clinical Utility of … (Continued) 17

CLINICAL PROFILING, FUTURE GOALS 18

MOLECULAR PROFILING APPROACHES 19

TABLE 1 DIFFERENT TOOLS FOR MOLECULAR PROFILING OF CANCER 19

Molecular Profiling Approaches (Continued) 20

Chapter-4: CURRENT PROFILING TECHNIQUES

GENOMIC PROFILING 21

TABLE 2 LIST OF TECHNIQUES/TOOLS FOR GENOMIC PROFILING 22

GENOMIC PROFILING (CONTINUED) 23

TABLE 3 GENOMIC REVENUE AND FORECAST, THROUGH 2015 ($ MILLIONS) 24

FIGURE 1 GENOMIC REVENUE AND FORECAST, 2009–2015 ($ MILLIONS) 24

GENOMIC PROFILING (CONTINUED) 25

MICROARRAYS 26

TABLE 4 COMMONLY USED DNA MICROARRAYS 27

Oligonucleotide Microarrays 27

Spotted Microarrays 28

Spotted Microarrays (Continued) 29

Microarrays and Applications 30

COMPARATIVE GENOMIC HYBRIDIZATION (CGH) 31

Comparative Genomic Hybridization (Continued) 32

Array Comparative Genome Hybridization 33

Array … (Continued) 34

Applications of Array-CGH 35

CGH and Cancer 35

Array CGH and Neuroblastoma 35

Key Companies 36

TABLE 5 SELECTED COMPANIES WITH MICROARRAY TECHNOLOGIES 37

Company Descriptions 37

Arrayit Corp. 37

PerkinElmer 38

Invitrogen 39

Agilent 39

Roche 40

SINGLE NUCLEOTIDE POLYMORPHISM (SNP) 41

MULTI-COLOR FISH 42

SPECTRAL KARYOTYPING 42

Company 43

iKaryos Diagnostics, 43

DNA SEQUENCING 43

Emerging DNA sequencing Technologies 44

Fluorescent in situ Sequencing (FISSEQ) 44

Pyrosequencing 45

Massively Parallel Signature Sequencing (MPSS) 45

Single-Molecule Sequencing 45

Bacterial Artificial Chromosome (BAC)-end Sequencing 46

In vitro Clonal Amplification 46

Parallelized Sequencing 47

Sequencing by Ligation 47

Microfluidic Sanger Sequencing 47

Other sequencing technologies 47

Applications to Cancer 48

Sequencing Technologies, Market, and Their Applications 49

TABLE 6 COMPANIES WITH SEQUENCING TECHNOLOGIES 50

Key Companies 50

Key Companies (Continued) 51

The Next Next-Generation Companies 52

Company Descriptions 53

Illumina 53

Illumina (Continued) 54

Illumina Products 55

Complete Genomics 56

Complete …(Continued) 57

454 Life Sciences 58

Applied Biosystems 59

Applied … (Continued) 60

Patents and Sequencing 61

TABLE 7 SEQUENCING PATENTS AWARDED 62

Genomics and Cancer—Some Examples 63

TABLE 8 MUTATIONS IDENTIFIED IN CANCER 64

TABLE 8 (CONTINUED) 65

Mutations Predicting Resistance to Targeted Therapies 65

TRANSCRIPTOMIC PROFILING 66

TABLE 9 TRANSCRIPTOMIC TECHNIQUES 67

MICROARRAY-BASED GENE EXPRESSION PROFILING 67

MICROARRAY-BASED GENE … (CONTINUED) 68

SERIAL ANALYSIS OF GENE EXPRESSION (SAGE) 69

MRNA 70

DATA ANALYSIS AND DESIGN 70

Data Analysis and … (Continued) 71

Data Analysis and … (Continued) 72

TILING ARRAYS 73

QRT-PCR 73

APPLICATIONS TO CANCER 73

Applications … (Continued) 74

FUTURE 75

EPIGENOMIC PROFILING 75

OVERVIEW AND INTRODUCTION TO THE EPIGENETICS LANDSCAPE 75

Applications to Cancer 76

DNA Methylation 77

Covalent Histone Modifications 78

Covalent … (Continued) 79

Covalent … (Continued) 80

Histone Modifications in Cancer 81

Histone … (Continued) 82

microRNA 83

MicroRNA Technologies that Will Impact Diagnostics and Therapeutics 84

TABLE 10 MIRNA AND SIRNA-A COMPARISON 85

Epigenetic Changes and Cancer Stem Cells 86

Epigenetic Therapy of Cancer 87

Epigenetic Therapy … (Continued) 88

TABLE 11 EPIGENETIC DRUGS APPROVED BY THE U.S. FDA 89

Leading Epigenetic Companies 90

TABLE 12 SELECTED EPIGENETIC COMPANIES 91

Epigenetics and MicroRNA Profiling—Finding Pathways to Treatment 92

Currently Used MicroRNA Techniques 93

Currently Used … (Continued) 94

Human Cancer and Epigenetic Regulation of miRNAs 95

Human Cancer … (Continued) 96

TABLE 13 DIFFERENTIAL EXPRESSION OF MICRORNA IN CANCER 97

TABLE 14
EPI-MIRNAS REGULATING EFFECTORS OF THE EPIGENETIC MACHINERY 98

MicroRNAs and Therapeutic Applications in Cancer 98

MicroRNAs …(Continued) 99

MicroRNAs …(Continued) 100

MicroRNAs …(Continued) 101

Polymorphisms in MicroRNAs Associated with Cancer Risk 102

MicroRNAs as Prognostic and Therapeutic Biomarkers 102

microRNA as Therapeutic Targets 103

Computational Methods for Analysis of Cellular Functions and Pathways 104

Computational …(Continued) 105

TABLE 15 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN COLON CANCER 106

TABLE 15 (CONTINUED) 107

Anti-Cancer Drugs and microRNA Targets 107

Anti-Cancer … (Continued) 108

TABLE 16 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN PANCREATIC CANCER 109

Anti-Cancer … (Continued) 110

Anti-Cancer … (Continued) 111

Anti-Cancer … (Continued) 112

Case Study: Epigenetic Silencing of the Intronic microRNA Mir-342 in Colorectal Cancer 113

TABLE 17 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN CRC AND NORMAL COLORECTAL TISSUE 114

TABLE 18
MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN NORMAL COLON AND EARLY STAGE COLORECTAL CANCER (STAGES I AND II) 115

TABLE 19 MIRNAS DIFFERENTIALLY EXPRESSED IN EARLY- (I AND II) VS LATE-STAGE (III AND IV) DISEASE 116

TABLE 20 PATHWAYS TARGETED BY CRC MIRNAS 117

Diagnostic and Therapeutic microRNA Strategies in Cancer 118

Diagnostic and … (Continued) 119

Diagnostic and … (Continued) 120

TABLE 21 MICRORNAS AS PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS: POTENTIAL EFFECT ON BREAST CANCER MANAGEMENT 121

Therapeutic Potential 122

Therapeutic Potential (Continued) 123

Therapeutic Potential (Continued) 124

TABLE 22 MICRORNAS (MIRS) WITH ALTERED EXPRESSION IN OVARIAN CARCINOMA 125

TABLE 22 (CONTINUED) 126

Therapeutic Potential (Continued) 127

Therapeutic Potential (Continued) 128

Outstanding Researchers 129

Implications for Cancer 130

TABLE 23 SELECTED MICRORNAS IN DEVELOPMENT AND CANCER 131

MicroRNA Clinical Trials 132

TABLE 24 ACTIVE CANCER CLINICAL TRIALS STUDYING MICRORNA PROFILING 132

TABLE 24 (CONTINUED) 133

Ongoing Active Trials 133

Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer 133

Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in situ 134

Study of Specimens from Young Patients With Neuroblastoma 134

Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia 135

The Molecular Characterization of Multiple Myeloma at Relapse 136

Molecular Analysis of Solid Tumors 137

A Study of Avastin (Bevacizumab) in Combination With Neoadjuvant Treatment Regimens in Patients With Primary HER2 Negative Breast Cancer Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia 137

Genetics Study of Tissue Collected from Patients with Acute Myeloid Leukemia 138

Blood Samples from Patients with Non–Small Cell Lung Cancer and from Healthy Volunteers 138

Biological Factors Predicting Response to Chemotherapy in Advanced Non–Small Cell Lung Cancer 139

Chemotherapy and Radiation Therapy with or without Cetuximab in Treating Patients with Stage IIIA Non–Small Cell Lung Cancer 139

Azacytidine and Bortezomib in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes 139

Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer 140

Study of Erlotinib with Docetaxel in Selected Non Small Cell Lung Cancer Patients in First-Line Treatment 141

Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan 142

microRNA Expression in Renal Cell Carcinoma 143

Bortezomib and Azacitidine in Treating Patients with Relapsed or Refractory T-Cell Lymphoma 143

Pharmacogenomic Study in Myeloma Patients Treated with Melphalan-Prednisone-Thalidomide or Lenalidomide-Dexamethasone 144

Study of CS-7017 in Combination with FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy 145

Integrated Whole-Genome Analysis of Hematologic Disorders 145

Unlocking Biological Processes 145

MicroRNA Patents and Outlook 146

TABLE 25 MICRORNA PATENTS 147

MicroRNA Patents and Outlook (Continued) 148

TABLE 26 MICRORNA MARKET AND FORECAST, 2015 ($ MILLIONS) 149

FIGURE 2 MICRORNA MARKET AND FORECAST, 2009-2015 ($ MILLIONS) 149

Key miRNA Companies 150

Invitrogen 150

Illumina 150

Exiqon 150

LC Sciences 151

TABLE 27 SELECTED COMPANIES FOR MIRNA-SPECIFIC TOOLS AND REAGENTS 152

Agilent 153

SuperArray 153

Applied Biosystems 153

SABiosciences 153

Qiagen 154

Methylation Markers 154

DNA Methylation, an Epigenetic Process 155

Current Methods and Products 156

Current …(continued) 157

Current … (Continued) 158

Cancer-specific Methylation Biomarkers 159

Cancer-…(Continued) 160

Clinical Implications 161

Epigenetic Drugs 161

TABLE 28 EPIGENETIC PROFILING MARKET AND FORECAST, THROUGH 2015 ($ MILLIONS) 162

FIGURE 3 EPIGENETIC PROFILING MARKET AND FORECAST, 2009–2015 ($ MILLIONS) 163

Epigenetic Diagnostic Development 163

TABLE 29 SELECTED METHYLATION TESTS FOR CANCER 164

Epigenetic Therapeutic Development 164

Epigenetic … (Continued) 165

TABLE 30 EPIGENETIC DRUGS FOR CANCER-APPROVED /LATE STAGE CLINICAL TRIAL 166

TABLE 31 CLINICAL STAGE HDAC INHIBITORS 167

Key Players 168

CellCentric 168

Epigenomics 168

Epizyme 169

Abbott 169

Veridex 170

OncoMethylome Sciences 170

OncoMethylome …(Continued) 171

TABLE 32 METHYLATION MARKERS IN DEVELOPMENT 172

Quest Diagnostics 173

TABLE 33 SELECTED COMPANIES WITH METHYLATION PRODUCTS 174

Orion Genomics 174

SABiosciences 175

Zymo Research 176

BioChain 176

EpigenDx 177

Millipore 177

Rubicon Genomics 177

Roche NimbleGen 178

SeqWright 178

Qiagen 179

EXACT Sciences Corporation 180

TABLE 34 METHYLATION MARKERS/TESTS- PATENTS 181

Active Motif 182

Active Motif (Continued) 183

Clinical Implications 184

OncoMethylome Sciences-GST-Pi/APC Methylation Test for Detection of Prostate Cancer 184

OncoMethylome …(Continued) 185

Methylation Markers: Novel Ideas in Development 186

Methylation … (Continued) 187

PROTEOMICS 188

PROTEOMICS AND PROTEIN PROFILING 189

Proteomics and … (Continued) 190

TECHNIQUES 191

TABLE 35 BIOMARKERS INDENTIFIED USING TWO-DIMENSIONAL ELECTROPHORESIS (2-DE) 192

TABLE 36 BIOMARKERS INDENTIFIED USING MASS SPECTROSCOPY (MS) 193

Techniques (Continued) 194

APPLICATIONS OF PROTEOMIC TECHNIQUES IN CANCER RESEARCH 195

TECHNOLOGIES AND LIMITATIONS 196

PROTEOMICS AND INITIATIVES 197

APPLICATIONS TO CANCER 198

Applications to Cancer (Continued) 199

PROTEOMICS IN THE TREATMENT OF CANCER 200

Proteomics in the …(Continued) 201

CLINICAL APPLICATIONS OF PROTEOMICS 202

Clinical Applications … (continued) 203

Clinical Applications … (continued) 204

Clinical Applications … (continued) 205

Clinical Applications … (continued) 206

Clinical Applications … (continued) 207

PROTEOMIC APPROACHES IN THERAPEUTIC TARGETS 208

Proteomic Approaches … (Continued) 209

KEY PLAYERS 210

Kreatech Biotechnology 210

Thermo Fisher Scientific 210

GE Healthcare 211

ProteinOne 211

Waters 211

PerkinElmer 212

Protneteomix 213

Whatman 213

Arrayit Corporation 214

Nutricognia 215

Qiagen 215

Luminex 216

TABLE 37 ANTIBODY ARRAY VENDORS 216

Clontech and Sigma 216

RayBiotch 217

ANALYTICAL SOFTWARE 217

Alphalyse 217

Protneteomix 217

THERAPEUTIC AND DIAGNOSTIC COMPANIES 218

Protein Biotechnologies and BioServe 218

Agendia 218

Aptagen, Inc 218

Protein Genesis 219

Aurelium 219

AxCell 219

Celera 220

Cellzome 220

Cognia 220

Eprogen 220

Europroteome 221

Genomic Solutions 221

Glaucus Proteomics 221

Hybigenics 221

PROTEOMICS-BASED DIAGNOSTIC PRODUCTS 222

Matritech 222

MDS Proteomics 222

Myriad Genetics 222

NextGen Sciences 223

ProFACT Proteomics 223

Protein Pathways 223

Proteologics 224

Proteome Factory AG 224

Proteome Sciences 224

Proteome Systems 225

Proteom Tech 225

Protiveris 225

Quattromed 225

Scimagix ProteinMin 225

Sense Proteomic limited 226

Signature BioScience 226

SomaLogic 226

Structural Bioinformatics (SBI) 226

Structural GenomiX (SGX) 226

WITA Proteomics 227

Xerion Pharmaceuticals 227

Zyomyx 227

PROTEOMICS IN INDUSTRY 227

PROTEOMIC RESEARCH CENTERS 228

Stanford University: Molecular Therapeutics Program 228

Vanderbilt University—Mass Spectrometry Research Center (MSRC) 228

Vanderbilt University…(Continued) 229

Vanderbilt University…(Continued) 230

CLINICAL TRIAL USING PROTEOMICS TECHNOLOGIES FOR PERSONALIZED MEDICINE 231

PROTEOMICS AND MARKET 231

TABLE 38 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, THROUGH 2015 ($ MILLIONS) 232

FIGURE 4
PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, 2009–2015 ($ MILLIONS) 232

GLYCOMICS 233

WHAT IS GLYCOMICS? 233

TECHNIQUES 234

ANALYTICAL HIGH-THROUGHPUT TECHNOLOGIES 235

EMERGENCE OF GLYCOARRAYS 236

GLYCOINFORMATICS 237

BIOMEDICAL APPLICATIONS 237

Biomedical Applications (Continued) 238

GLYCOMICS' RELATIONSHIP WITH OTHER "OMICS" TECHNOLOGIES 239

Glycomics for Biomarker Discovery 239

TABLE 39 THE SEVEN TUMOR GLYCOME LABORATORIES 239

TABLE 39 (CONTINUED) 240

Glycomics-biomarkers for Ovarian Cancer 240

Assessing Response to Neoadjuvant Chemotherapy with HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms. 241

TABLE 40 CLINICAL TRIALS AND GLYCOMICS 242

GLYCOMICS AND PATENTS 242

Carbohydrate Encapsulated Nanoparticles 242

Glycosylated Specificity Exchangers (Tripep) 242

Glycosylated Specificity Exchangers (Tripep) 242

Tripep AB /ChronTech Pharma AB 242

TABLE 41 GLYCOMICS PATENTS 243

Serum Marker for Measuring Liver Fibrosis 243

COMPANIES 244

Glycominds Limited 244

Endotis Pharma 245

Glykoz Pty. Ltd. 245

GP Biosciences Ltd. 245

METABOLOMICS 246

WHAT IS METABOLOMICS? 247

METABOLOME 247

TECHNIQUES 248

Detection Methods 249

METABOLOMICS AND DRUG DISCOVERY 250

BIOMARKER IDENTIFICATION 251

Biomarker Identification (Continued) 252

TABLE 42 ISSUED PATENTS 253

Chapter-5: BIOINFORMATICS, DATABASES, AND PATHWAY ANALYSIS

BIOINFORMATICS, DATABASES… 254

BIOINFORMATICS, DATABASES…(CONTINUED) 255

BIOINFORMATICS, DATABASES…(CONTINUED) 256

Chapter-6: CANCER PROFILING AND CASE STUDIES

CANCER PROFILING AND CASE STUDIES 257

CASE STUDIES 258

IN BREAST CANCER—THREE PERSPECTIVES ILLUSTRATING CURRENT CHALLENGES IN PERSONALIZED MEDICINE 258

In Breast Cancer—Three…(Continued) 259

GENE EXPRESSION PROFILING 260

Gene Expression Profiling (Continued) 261

Gene Expression Profiling (Continued) 262

Gene Expression Profiling (Continued) 263

BIOMARKERS 264

DIAGNOSTIC TESTS IN DEVELOPMENT 264

TABLE 43 DIAGNOSTIC TESTS IN DEVELOPMENT 265

Approved Tests 265

Approved Tests (Continued) 266

TABLE 44 APPROVED DIAGNOSTIC TESTS 267

Cancer and Biomarkers 268

TABLE 45 KEY PREDICTIVE BIOMARKERS FOR TRASTUZUMAB THERAPY 269

Approved Tests (Continued) 270

Approved Tests (Continued) 271

TABLE 46 PREDICTIVE BIOMARKERS FOR EGFR TKI THERAPIES IN LUNG CANCER 272

Approved Tests (Continued) 273

Approved Tests (Continued) 274

Approved Tests (Continued) 275

Approved Tests (Continued) 276

FUTURE DIRECTIONS 277

Future Directions (Continued) 278

TABLE 47 PREDICTIVE BIOMARKERS FOR ANTI-EGFR ANTIBODY THERAPIES IN COLORECTAL CANCER 279

Future Directions (Continued) 280

Chapter-7: MARKET

GENOMICS MARKET 281

TRENDS 281

TABLE 48 GENOMICS MARKET REVENUE AND FORECAST, THROUGH 2015 ($ MILLIONS) 281

FIGURE 5
GENOMICS MARKET REVENUE AND FORECAST 2009–2015 ($ MILLIONS) 282

Genotyping and Gene Expression 282

TABLE 49 GENOTYPING MARKET AND FORECAST, THROUGH 2015 ($ MILLIONS) 283

FIGURE 6 GENOTYPING MARKET AND FORECAST, 2009–2015 ($ MILLIONS) 283

TABLE 50 GENE EXPRESSION MARKET AND FORECAST, THROUGH 2015 ($ MILLIONS) 284

FIGURE 7 GENE EXPRESSION MARKET AND FORECAST, 2009–2015 ($ MILLIONS) 284

MICROARRAY MARKET 285

The Global Market for Microarray 285

TABLE 5
GLOBAL MICROARRAY MARKET FORECAST, THROUGH 2015 ($ MILLIONS) 286

FIGURE 8 GLOBAL MICROARRAY MARKET FORECAST, 2009–2015 ($ MILLIONS) 286

TABLE 52 THE DIAGNOSTIC MICROARRAY MARKET AND FORECAST, THROUGH 2015 ($ MILLIONS) 287

FIGURE 9 THE DIAGNOSTIC MICROARRAY MARKET AND FORECAST, 2009–2015 ($ MILLIONS) 288

The Global Market … (Continued) 289

TABLE 53 MICROARRAY TECHNOLOGIES: COMPANIES AND PRODUCTS 290

TABLE 54 DNA MICROARRAY TECHNOLOGIES: COMPANIES AND REVENUE, THROUGH 2010 ($ MILLIONS) 290

FIGURE 10 DNA MICROARRAY TECHNOLOGIES: COMPANIES AND REVENUE, 2008-2010 ($ MILLIONS) 291

TABLE 55 AGILENT TECHNOLOGIES: ORDERS AND NET REVENUE, 2009 AND 2010 ($ MILLIONS) 291

TABLE 56 DNA MICROARRAY COMPANIES' SALES AND FORECASTS, 2009 AND 2010 ($ MILLIONS) 292

FIGURE 11 DNA MICROARRAY COMPANIES' SALES AND FORECAST, 2009–2010 ($ MILLIONS) 293

The Global Market … (Continued) 294

The Global Market … (Continued) 295

The Global Market … (Continued) 296

The Global Market … (Continued) 297

The Global Market … (Continued) 298

Sequencing and Market 299

TABLE 57 SEQUENCING—SALES AND FORECAST, THROUGH 2015 ($ MILLIONS) 299

FIGURE 12 SEQUENCING—SALES AND FORECAST, 2009–2015 ($ MILLIONS) 300

Future 301

Future (Continued) 302

TABLE 58 ILLUMINA—REVENUE AND FORECAST, 2008-2010 ($ MILLIONS) 303

FIGURE 13 ILLUMINA—REVENUE AND FORECAST, 2008, 2009, 2010 ($ MILLIONS) 303

TABLE 59 SELECTED COMPANIES AND SEQUENCING PRODUCTS 304

TABLE 60 LIFE TECHNOLOGIES REVENUES AND FORECAST, 2008-2010 ($ MILLIONS) 305

FIGURE 14 LIFE TECHNOLOGIES REVENUES AND FORECAST, 2008-2010 ($ MILLIONS) 305

PCR Market 306

TABLE 61 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST THROUGH 2015 ($ MILLIONS) 307

FIGURE 15
GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, 2009–2015 ($ MILLIONS) 307

TABLE 62 REAL-TIME (QRTPCR) PCR SELECTED COMPANIES 308

PCR Market (Continued) 309

TABLE 63 REAL-TIME (QRT-PCR) MARKET, THROUGH 2015 ($ MILLIONS) 310

FIGURE 16 REAL-TIME (QRT-PCR) MARKET, 2009-2015 ($ MILLIONS) 310

EPIGENETICS AND MARKET 311

TABLE 64 GLOBAL EPIGENETIC MARKET AND FORECAST, THROUGH 2015 ($ MILLIONS) 311

FIGURE 17 GLOBAL EPIGENETIC MARKET AND FORECAST, 2009-2015 ($ MILLIONS) 312

TABLE 65 EPIGENETICS ARRAYS AND SELECTED CANCER PROFILING COMPANIES 313

EPIGENETIC THERAPEUTICS 314

Epigenetic Therapeutics (Continued) 315

TABLE 66 EPIGENETICS AND SELECTED COMPANIES 316

EPIGENETICS AND DIAGNOSTIC TESTS 317

TABLE 67 EPIGENETIC DIAGNOSTIC TESTS 317

MIRNA MARKET 317

miRNA Market (Continued) 318

TABLE 68 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2015 ($ MILLIONS) 319

FIGURE 18 TOTAL MIRNA MARKET AND FORECAST, 2009-2015 ($ MILLIONS) 319

TABLE 69 TOTAL MIRNA MARKET SALES, 2008 (%) 320

EPIGENETICS AND CANCER MARKET AND FUTURE GROWTH 321

TABLE 70 SELECTED COMPANIES WITH METHYLATION PRODUCTS 321

CURRENT USE OF PROTEOMICS IN THE PHARMA INDUSTRY 321

TABLE 71 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, THROUGH 2015 ($ MILLIONS) 322

FIGURE 19 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, 2009-2015 ($ MILLIONS) 322

TABLE 72
PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, THROUGH 2015 ($ MILLIONS) 323

FIGURE 20 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, 2009-2015 ($ MILLIONS) 323

PROTEIN MICROARRAYS AND TRENDS 324

Protein Microarrays and … (Continued) 325

THE METABOLOMICS MARKET 326

CONCLUSION 327

TABLE 73 SELECTED COMPANIES OFFERING, DEVELOPING, OR PARTNERING TO DEVELOP COMPANION DIAGNOSTICS 328

TABLE 73 (CONTINUED) 329

Chapter-8: SELECTED LICENSING, COLLABORATIONS AND MERGERS

CLC BIO, ION TORRENT PARTNER ON MDX PROJECT 330

ASURAGEN IN-LICENSES BRAF MUTATION FROM JOHNS HOPKINS 330

GSK TO EXPLOIT SUPERGEN'S EPIGENETICS EXPERTISE IN CANCER COLLABORATION 331

AGENDIA AND AGILENT TECHNOLOGIES ANNOUNCE PLANS TO JOINTLY DEVELOP NEW DIAGNOSTIC TESTS 331

GENOTYPING—KAISER PERMANENTE AND THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF) ENTERED INTO AN AGREEMENT WITH AFFYMETRIX TO CONDUCT GENOME-WIDE ANALYSES OF DNA SAMPLES 332

NEW GENOMIC CANCER CARE ALLIANCE FORMED TO STUDY WHOLE-GENOME SEQUENCING IN CANCER TREATMENT 333

Chapter-9: COMPANY PROFILES

TABLE 74 MICROARRAY COMPANIES 334

TABLE 74 (CONTINUED) 335

OTHER KEY COMPANIES 335

MICRORNA 335

Asuragen 335

Regulus Therapeutics 335

Alnylam Pharmaceuticals 336

Isis Pharmaceuticals 336

LC Sciences 337

DNAVision 337

METHYLATION MARKERS 337

TABLE 75 METHYLATION PRODUCTS: SELECTED COMPANIES 338

TABLE 76 SELECTED PROFILING COMPANIES 339

CONCLUSIONS 339

Conclusions (Continued) 340

Chapter-10: REFERENCES

To order this report:Biotechnology Industry: Cancer Profiling and Pathways: Technologies and Global Markets

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):